Test Results

A report will be sent to the physician within one week of the specimen arriving at Aureon. Each report focuses on the patient’s individualized results including:

• Disease Progression Score (0-100): reflects the likelihood of the patient developing Disease Progression (defined as bone/soft tissue metastases, death of disease and/or androgen independent rise in PSA within eight years of their diagnosis)
• Favorable Pathology: The favorable pathology endpoint predicts the likelihood of a favorable outcome post-prostatectomy, i.e., prostatectomy Gleason score <6 (no pattern 4 or 5), <pT2 and PSA nadir post-prostatectomy
• Quantitative Morphometric Features: describes the objective quantification of a number of features from the digital image of the H&E sample
• Photomicrographs: segmented and classified images
• Biomarkers: provides an interpretation of a number of protein markers if ordered separately by the physician